Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Current Quarter	$-0.18	Next Quarter	$-0.18
Current Year	$-0.71	Next Year	$-0.59
QoQ Growth	+0.0%	YoY Growth	+16.9%
3Y EPS CAGR	+56.9%	Target Price	$9.50
Consensus	Buy	Upside	+210.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GOSS	$3.06	-1.61%	2.74M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GOSS	$3.06	-1.6%	2.74M
3
4
5
6

GOSS

GOSS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Gossamer Bio Inc. Data in Excel

Get Gossamer Bio Inc. Data in Excel